Characterization of the Platelet Prostaglandin D₂ Receptor: LOSS OF PROSTAGLANDIN D₂ RECEPTORS IN PLATELETS OF PATIENTS WITH MYELOPROLIFERATIVE DISORDERS

Prostaglandin (PG) D₂ is synthesized in platelets at concentrations which could inhibit aggregation via activation of adenylate cyclase. To more directly define platelet-PG interactions, a binding assay has been developed for platelet PG receptors with [³H]PGD₂ as ligand. [³H]PGD₂ binding to intact platelets was saturable and rapid with the ligand bound by 3 min at 20°C. PG competed with the [³H]PGD₂ binding site with a potency series: PGD₂ (IC₅₀ = 0.08 μM) ≫ PGI₂ (IC₅₀ = 2 μM) > PGE₁ (IC₅₀ = 6 μM) > PGF_2α (IC₅₀ = 8 μM). Scatchard analysis of binding data from six normal subjects showed a single class of binding sites with a dissociation constant (K_d) of 53 nM and 210 binding sites per platelet. This PGD₂ receptor assay was then used to study platelets from five patients with myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and chronic myelogenous leukemia), as over 90% of these patients have platelets resistant to the effects of PGD₂ on aggregation and adenylate cyclase activity (1978. Blood.52: 618-626.). In the presence of 50 nM [³H]PGD₂, the patients' platelets bound 7.1±2.9 fmol ligand/10⁸ platelets compared with 15.1±1 fmol/10⁸ platelets in normals, a decrease of 53% (P < 0.01). Scatchard analysis showed that the K_d of [³H]PGD₂ binding (33 nM) was comparable to normal platelets, which indicates that the decreased PGD₂ binding in these platelets represented fewer receptors rather than altered affinity of the ligand for the binding site. The 53% decrease in [³H]PGD₂ binding correlated with a 48% decrease in PGD₂-activated platelet adenylate cyclase. The characterization of the platelet PGD₂ binding site provides further direct evidence that there are at least two PG receptors on platelets, one for PGE₁ and PGI₂, and a separate receptor for PGD₂. Direct binding analysis will be a useful tool for studying the role of PG in regulating platelet function, as demonstrated by the selective loss of PGD₂ binding sites in patients with myeloproliferative disorders.

Click on an image below to see the page. View PDF of the complete article

page 586

page 587

page 588

page 589

page 590